PE 22-28
PE 22-28 from the Nexus Cognitive & Nootropic catalog, supplied for controlled in-vitro research workflows.
Ships from the US with tracking.
Catalog active: Catalog pricing is active. Live warehouse counts are not published.
Certificate pending — assay values withheld
Final assay values publish here once independent documentation is available. See the verification process.
For in-vitro research use only. Not for human consumption.
PE-22-28 is a synthetic peptide that inhibits the TREK-1 potassium channel (two-pore domain K+ channel). TREK-1 inhibition has been linked to increased serotonergic signaling and BDNF expression. It is studied as a potential rapid-onset antidepressant-like compound and nootropic in preclinical research models.
PE 22-28 definition
PE 22-28 is a synthetic 7-amino-acid peptide derived from spadin (a sortilin-derived peptide). Research models examine its interaction with TREK-1 potassium channels, which are studied in CNS-pathway research models. The compound is a research-context spadin-pathway analog. Research use only.
No sequence is listed in the current catalog record for this product.
- CAS
- 1801959-12-5
- MW
- 773.9 g/mol
- Sequence
- Not listed
- Half-life
- Not listed
- Formula
- C35H55N11O9
- Purity
- Certificate pending
- Form
- Lyophilized powder
- Class
- TREK-1 Channel Inhibitor / Nootropic Peptide
The dossier.
Compound Overview
PE-22-28 is a synthetic peptide that inhibits the TREK-1 potassium channel (two-pore domain K+ channel). TREK-1 inhibition has been linked to increased serotonergic signaling and BDNF expression. In preclinical research models, the compound is studied in relation to rapid-onset antidepressant-like and nootropic research pathways.
Research Background & Published Literature
PE-22-28 comes from the spadin research reported in Nature Medicine by Mazella et al. (2010) at IPMC-CNRS. The compound is an optimized fragment used to examine TREK-1-mediated signaling and mood-related neurotransmitter pathways with improved stability in controlled research settings.
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:
Storage, Handling & Stability Guidelines
Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.
- Keep time at ambient temperature as brief as practical during handling to support compound integrity.
- Reseal vials promptly after each withdrawal to reduce moisture exposure.
- Use appropriate personal protective equipment and follow your institution's chemical safety protocols at all times.
- For traceability, label aliquots with compound name, concentration, reconstitution date, and operator initials.
Quality Assurance & Lab Verification
The Certificate of Analysis for this catalog item is pending. No provisional batch, assay, method, analyst, or release data is published in this product dossier. Check the Lab Verified archive for documentation status.
Shipping
Orders ship within the United States via USPS; international orders are not accepted. Laboratories should follow their validated SOP together with any handling fields published for the represented product or lot; no universal prepared-solution condition is inferred here.
Compound details.
- Molecular Weight
- 773.9 g/mol
- Class
- Spadin-derived peptide (residues 22-28)
- Sequence length
- 7 residues
- Research target
- TREK-1 potassium channel
Research context.
Studied in preclinical research models examining TREK-1 channel pharmacology, CNS signaling research, and spadin-pathway research. Research use only.
Verification standard.
Certificate information is lot-specific. A finalized public record shows only the methods, fields, and results present for that named lot. A pending certificate state exposes no assay values and must not be interpreted as analytical verification. Review Nexus lab verification.
Certificate status.
Finalized independent certificate documentation is pending for this catalog record. Measurement details remain withheld until the certificate is available.
- Sequence
- Not listed
- Model preview
- Unavailable
Molecular model preview is unavailable for this catalog record.
The chemistry.
7-amino acid peptide fragment of the prion protein-derived compound, spadin analog
Technical specifications.
- Product Name: PE-22-28 5mg
- Classification: TREK-1 Channel Inhibitor / Nootropic Peptide
- Structural Description: 7-amino acid peptide fragment of the prion protein-derived compound, spadin analog
- Molecular Weight: 773.9 g/mol
- Purity: ≥99% (verified by HPLC and Mass Spectrometry)
- Physical Form: Lyophilized (freeze-dried) powder
- Intended Use: In-vitro research use only — not for human consumption
Related research compounds
Comparable catalog records with published variants and certificate status.
- Cognitive & NootropicVerified batchSelankPriceFrom $35.99Formats3 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 129954-34-3View product - Cognitive & NootropicVerified batchSemaxPriceFrom $32.99Formats3 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 80714-61-0View product - Cognitive & NootropicCertificate pendingNA Selank amidatePrice$89.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product - Cognitive & NootropicCertificate pendingNA Semax amidatePrice$79.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product - Cognitive & NootropicCertificate pendingSemax 10mg+Selank 10mgPrice$84.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product
PE 22-28 research FAQ.
What is PE 22-28 used for in research?
PE 22-28 is supplied for controlled in-vitro research workflows in the Cognitive & Nootropic category. It is not labeled for human or veterinary use.
Does PE 22-28 have a finalized analytical record?
PE 22-28 is listed with certificate-pending status until a finalized lot-specific COA record is available.
Which PE 22-28 variants are published?
Published Nexus variants include 10mg.
Does PE 22-28 include a COA?
The current Nexus record marks PE 22-28 as certificate pending; finalized assay values are not shown until lot-specific documentation is available.